This study aims to test the safety and effectiveness of a new drug, ACR-368, for treating certain types of cancer. The cancers being studied are ovarian carcinoma (ovarian cancer), endometrial adenocarcinoma (cancer in the lining of the uterus), and urothelial carcinoma (bladder cancer). Participants will take ACR-368 alone or with a very low dose of another drug called gemcitabine. The study uses a special test called OncoSignature® to decide which treatment is best for each person. Patients will stay in the study until their cancer worsens, they experience severe side effects, or they decide to stop. To join, participants need to have specific medical conditions and meet certain requirements, like having a life expectancy of more than three months.
- Study Length: Until cancer worsens or unacceptable side effects occur.
- Participants receive either ACR-368 alone or with gemcitabine.
- Regular health checks and tests will be required.